Sierra Oncology, Inc.

If you purchased Sierra Oncology, Inc. securities and would like to join the action, please click "Join This Action" below.

SRRA STOCK ALERT: HALPER SADEH LLP IS INVESTIGATING WHETHER THE SALE OF SIERRA ONCOLOGY, INC. IS FAIR TO SHAREHOLDERS

April 13, 2022.

New York, New York—Halper Sadeh LLP, an investor rights law firm, is investigating whether the sale of Sierra Oncology, Inc. (NASDAQ: SRRA) to GlaxoSmithKline plc for $55.00 per share in cash is fair to Sierra Oncology shareholders.

The investigation concerns whether Sierra Oncology and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders by failing to, among other things: (1) obtain the best possible consideration for Sierra Oncology shareholders; (2) determine whether GlaxoSmithKline is underpaying for Sierra Oncology; and (3) disclose all material information necessary for Sierra Oncology shareholders to adequately assess and value the merger consideration. On behalf of Sierra Oncology shareholders, Halper Sadeh LLP may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.

Halper Sadeh LLP represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Scroll to Top